Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
269
datasets available to search
ShareScore release 0.9.0
Dataset results
269 results for “Antibody responses”
Data from: Genome-wide epitope mapping reveals significant diversity in antibody responses to Coxiella burnetii vaccination and infection
Open the record for dataset details and reuse information.
Data from: A longitudinal assessment of the antibody response to SARS-CoV-2 infection in the New Mexican population
Open the record for dataset details and reuse information.
Data from: Antibody responses to Plasmodium vivax Duffy binding and erythrocyte binding proteins predict risk of infection and are associated with protection from clinical malaria
Background. The Plasmodium vivax Duffy Binding Protein (PvDBP) is a key target of naturally acquired immunity. However, the functional receptor-binding region II of PvDBP (PvDBPII) is highly polymorphic. The natural acquisition of antibodies to different variants of PvDBPII, including AH, O, P and Sal1 alleles, the central region III-V, and P. vivax Erythrocyte Binding Protein region II (PvEBPII) and their associations with risk of clinical P. vivax malaria are not well understood. Methodology. Total IgG and IgG subclasses 1, 2, and 3 that recognize four alleles of PvDBPII (AH, O, P, and Sal1), PvDBPIII-V and region II of PvEBP (PvEBPII) were measured in samples collected from a cohort of Papua New Guinean (PNG) children of aged 1-3 years living in a highly endemic area of PNG. The levels of binding inhibitory antibodies (BIAbs) to PvDBPII (AH, O, and Sal1) were also tested in a subset of children. The association of presence of IgG with age, cumulative exposure (measured as the product of age and malaria infections during follow-up, i.e. molFOB) and prospective risk of clinical malaria were evaluated. Results. Increase in antigen-specific total IgG, IgG1, and IgG3 with age and cumulative exposure was only observed for PvDBPII AH and PvEBPII. High total IgG responders and IgG3 specific responses to the predominant PvDBPII AH allele, were associated with decreased incidence of clinical P. vivax episodes (aIRR=0.56-0.68, P=<0.001-0.021 ). High total IgG and IgG1 to PvEBPII correlated more strongly with protection against clinical vivax malaria compared with those of all PvDBPII variants (aIRR=0.38, P<0.001). Antibodies to PvDBPII AH and PvEBPII showed evidence of an additive effect, with a joint protective association of 70%. The six children with high levels of Binding Inhibitory Antibodies (BIAbs) to PvDBPII and high strain-transcending blocking ability (i.e. >80%) tended to have less clinical diseases (IRR=0.45, P=0.083). Conclusion. Antibodies to the key parasite invasion ligands PvDBPII and PvEBPII are good correlates of protection against P. vivax malaria in PNG. This further strengthens the rationale for inclusion of PvDBPII in a recombinant subunit vaccine for P. vivax malaria and highlights the need for further functional studies to determine the potential of PvEBPII as a component of a subunit vaccine for P. vivax malaria.
Bats generate lower affinity, but higher diversity antibody responses compared to mice, an effect that can be manipulated with diet
<p><span>Bats are reservoirs of many zoonotic viruses that are fatal in humans but do not cause disease in bats. Moreover, bats generate low neutralizing antibody titers in response to experimental viral infection, although more robust antibody responses have been observed in wild caught bats during times of food stress. Here we compared the antibody titers and B cell receptor (BCR) diversity of Jamaican fruit bats (<em>Artibeus jamaicensis</em>; JFB) and BALB/c mice generated in response to T-dependent and T-independent antigens. We then manipulated the diet of JFBs and challenged them with H18N11 influenza A-like virus or a replication incompetent Nipah virus VSV (Nipah-riVSV). Under standard housing conditions, JFBs generated a lower avidity antibody response and possessed more BCR mRNA diversity compared to BALB/c mice. However, withholding protein from JFBs improved serum neutralization in response to Nipah-riVSV and improved serum antibody titers specific to H18 but reduced BCR mRNA diversity. </span></p>
Resources of "Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1"
<p>Resources of the article "Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1". See https://github.com/yunlongcaolab/SARS-CoV-2-JN.1-mAbs for future updates.</p>
Code related to article "The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients"
<p>This code is related to article "The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients"</p> <p>Abstract</p> <p>The factors involved in the persistence of antibodies to SARS-CoV-2 are unknown. We evaluated the antibody response to SARS-CoV-2 in personnel from 10 healthcare facilities and its association with individuals’ characteristics and COVID-19 symptoms in an observational study. We enrolled 4735 subjects (corresponding to 80% of all personnel) over a period of 5 months when the spreading of the virus was drastically reduced. For each participant, we determined the rate of antibody increase or decrease over time in relation to 93 features analyzed in univariate and multivariate analyses through a machine learning approach. In individuals positive for IgG ( ≥ 12 AU/mL) at the beginning of th study, we found an increase [p= 0.0002] in antibody response in symptomatic subjects, particularly with anosmia/dysgeusia (OR 2.75, 95% CI 1.753 – 4.301), in a multivariate logistic regression analysis. This may be linked to the persistence of SARS-CoV-2 in the olfactory bulb.</p>
Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose
ClinicalTrials.gov study NCT02514746. IPD Sharing: Not stated. Countries: 0. Publications: 2.
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
ClinicalTrials.gov study NCT05899816. IPD Sharing: YES. Countries: 2. Publications: 1.
Antibody Response to Influenza Vaccine in Patients With Sarcoidosis
ClinicalTrials.gov study NCT00828828. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
ClinicalTrials.gov study NCT02240888. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose
ClinicalTrials.gov study NCT01173302. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)
ClinicalTrials.gov study NCT02759354. IPD Sharing: YES. Countries: 0. Publications: 1.
Monoclonal Antibody Duration of REsponse in MIgraine After Treatment Interruption
ClinicalTrials.gov study NCT05232942. IPD Sharing: UNDECIDED. Countries: 1. Publications: 20.
COVID-19 Antibody Responses In Cystic Fibrosis
ClinicalTrials.gov study NCT04904445. IPD Sharing: NO. Countries: 1. Publications: 21.
Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients
ClinicalTrials.gov study NCT02434133. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Impact of Vitamin D Supplementation on COVID-19 Vaccine Response and IgG Antibodies in Deficient Women.
ClinicalTrials.gov study NCT05447065. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine
ClinicalTrials.gov study NCT02095314. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Antibody Response to COVID-19 Vaccines in Liver Disease Patients
ClinicalTrials.gov study NCT04775069. IPD Sharing: NO. Countries: 1. Publications: 4.
Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booste
ClinicalTrials.gov study NCT00625677. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B
ClinicalTrials.gov study NCT03125616. IPD Sharing: NO. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.